Please assess the completion status of the following clinical trial:

Trial Title: Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed anaplastic or poorly differentiated variant thyroid carcinoma of either of the following:~  * Regionally advanced disease~    * Confined to the neck and/or superior mediastinum (i.e., above the level of the carina)~   * Measurable or evaluable\* disease~ * Completely resected disease without measurable or evaluable disease NOTE: \*At a minimum, abnormalities on physical exam or radiographic studies that may not be precisely measured but readily followed~* Must have original/diagnostic tumor blocks available to confirm histopathology and for tumor microvessel density immunohistochemistry~  * Patients with no available original/diagnostic tumor blocks must have tumor accessible for pretreatment needle core biopsy~* Must undergo indirect and direct laryngoscopy to ensure patency of the trachea/airway if deemed inoperable, with bulky thyroid/neck masses and/or suspicion of airway obstruction~* No distant metastases, including but not limited to, brain metastases, disease below the level of the carina, pulmonary parenchyma, and hepatic or bony metastases~  * Superior mediastinal disease (i.e., above the level of the carina) in addition to regional neck disease is allowed provided the disease can be contained in a single radiotherapy port~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Hemoglobin ≥ 8.5 g/dL~Hepatic~* Bilirubin ≤ 1.5 mg/dL~* ALT and AST ≤ 3.5 times upper limit of normal~Renal~* Creatinine ≤ 1.5 mg/dL~Cardiovascular~* LVEF ≥ 50% by echocardiogram~* EKG normal~* No prior angina~* No prior myocardial infarction (e.g., significant Q waves), QTc \> 450 msec, or other clinically significant abnormalities on ECG~* No congestive heart failure~* No uncontrolled atrial arrhythmias or clinically significant arrhythmias, including any of the following:~  * Conduction abnormality~ * Nodal junctional arrhythmias and dysrhythmias~ * Sinus bradycardia or tachycardia~ * Supraventricular arrhythmias~ * Atrial fibrillation or flutter~ * Syncope or vasovagal episodes~* No significant heart wall abnormality or heart muscle damage by echocardiogram~* No uncontrolled hypertension (i.e., blood pressure consistently greater than 150/100 mm Hg irrespective of medication)~  * Hypertension is allowed provided there is clinical documentation of controlled blood pressure for 2 months before study entry~* No symptomatic peripheral vascular disease or cerebrovascular disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No uncontrolled hypokalemia or hypomagnesemia~* No concurrent serious infection~* No other nonmalignant uncontrolled medical illness or one whose control may be jeopardized by the complications of study therapy~* No grade 2 or greater pre-existing motor or sensory peripheral neuropathy~* No psychiatric disorder or other condition that would preclude study compliance~* No conditions associated with QTc prolongation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent biologic therapy~* No concurrent immunotherapy~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy, except for the following:~  * Gonadotropin-releasing hormone agonists for patients with hormone-refractory prostate cancer~ * Hormone replacement therapy~ * Oral contraceptives~ * Megestrol for anorexia/cachexia~Radiotherapy~* No prior radiotherapy~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~* Prior attempt at resection or cytoreduction (e.g., debulking) surgery irrespective of surgical margins allowed provided there are no distant metastases~* At least 1 week but no more than 8 weeks since prior surgery and recovered~Other~* No other concurrent cytotoxic therapy~* No other concurrent antineoplastic therapy~* No other concurrent investigational therapy~* No concurrent medications known to prolong the QTc interval unless the medication can be held for at least 4 days during each treatment course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues